Long-term management of multiple sclerosis patients treated with cladribine tablets beyond year 4 Article Swipe
YOU?
·
· 2022
· Open Access
·
· DOI: https://doi.org/10.1080/14656566.2022.2106783
· OA: W4289995506
Continuous monitoring of disease activity during the treatment-free period is important. Subsequent management depends on the presence or absence of inflammatory disease activity, determined in the absence of consistent guidelines via practice-driven neurological decision criteria. Persisting or newly occurring inflammatory disease activity is an indication for further treatment, i.e. either re-initiation of cladribine or switching to another highly effective disease-modifying therapy. The decision to retreat or switch should be based on clinical and radiological evaluation considering disease course, treatment history, and safety aspects. In the absence of disease activity, either retreatment can be offered, or the treatment-free period can be extended under structured monitoring.
